Page 11234..1020..»

British Society for Nanomedicine

§ September 24th, 2017 § Filed under Nano Medicine § Tagged Comments Off on British Society for Nanomedicine

Welcome to the British Society for Nanomedicine

With the global benefits of the new science of nanomedicine growing each year, the British Society for Nanomedicine has been created to allow open access for industry, academia, clinicians and the public to news and details of ongoing research throughout the UK

A new short course in nanotechnology is now available.

Only 14 places available so register soon.

What is Nanomedicine? Introducing applications of Nanotechnology

Saturday 12th May 2018

Nanomedicines are used globally to improve the lives of patients suffering from a range of disorders including cancer and various infectious diseases. Nanomedicines currently used clinically have overcome a number of issues associated with conventional drug delivery. This interactive workshop will introduce key areas in the development of nanomedicines. The course is presented by multidisciplinary researchers, with expertise in formulation, clinical application, and safety. Additionally, there will be the opportunity to discuss careers in academia. This course would benefit anyone with a general interest in current healthcare research.

University of Liverpool, 126 Mount Pleasant, L69 3GR

Presented by Dr Paul Curley, Dr James Hobson & Dr Neill Liptrott

Click here for more information

To see some of the presentations from this year’s European Nanomedicine Meeting in London click on the presenter’s name below:

Patrick Boisseau, ETPN, France

Nathalie Mignet, The French Society for Nanomedicine (SFNano)

Ulf Andersson, Chairman Nanomed North

Annette Bramley, EPSRC

Mark Platt, Loughborough University

Sylwia Sekula-Neuner, Karlsruhe Institute of Technology

Lea Ann Dailey, KCL, UK

Sven Even Borgos, SINTEF, Norway

Maria de la Fuente, Health Research Institute of Santiago de Compostela (IDIS), Spain

Klaus Weltring, German Platform NanoBioMedicine

Bassem Sabagh, PostNova

Editors-in-Chief Steve Rannard, Raj Bawa, Si-Shen Feng and Andrew Owen

The Journal of Interdisciplinary Nanomedicine (JOIN) is an international peer-reviewed academic journal that aims to provide truly interdisciplinary nanomedicine research. JOIN is now accepting submissions from all relevant fields to be included in the first issue.

The journal contains evidence-based research and translational outputs with high-level contributions from at least two sciences that are peer-reviewed by multiple reviewers tasked to focus primarily on their specialist areas. Multiple first and/or corresponding author status is encouraged so as to provide transparency and acknowledgment for contribution to multidisciplinary work. The Journal embraces submissions from all relevant fields as applied to early stage scientific developments and studies aimed at the progression of nanomedicines towards the clinic, which include engineering, science and medicine, especially materials sciences, life science, clinical science, intellectual property, regulatory issues and policy considerations. JOIN contains original research papers, editorials, review articles, technical notes, and letters to the editor about matters that may benefit the wider readership. Advances that are progressing to application through consolidation of multiple areas of expertise are especially encouraged. Core areas of particular interest include applications of new materials and biological concepts, targeted delivery, molecular biomaterials and nanotechnology in diagnostics, pharmacology, pharmaceutics, toxicology, and clinical outcomes.

For further details please lookhere

Continued here:
British Society for Nanomedicine

Read the Rest...

Nanomed Meeting 2018 | Nanomedicine Conferences| Nanotechnology …

§ September 20th, 2017 § Filed under Nano Medicine § Tagged Comments Off on Nanomed Meeting 2018 | Nanomedicine Conferences| Nanotechnology …

Meetings International proudly announces the Global Experts Meeting on International Conference and Exhibition onNanomedicine and Nanotechnology Conference scheduled during October 15-17 2018 at Osaka, Japan .With a theme of Challenges and Innovations in next generation medicine”.

Meetings International provides a Global Platform for Nanotechnology Professors, Medical and Healthcare Professionals to Exchange Ideas, Knowledge and Networking at its 100+ International Conferences.

TheNanotechnologymarket is valued at USD 12.54 Billion in 2016. This market is expected to grow at a CAGR of 11.7% during the forecast period to reach USD 21.87 Billion by 2021. The new title on Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” predicts that the total nanomedicine market globally will be worth USD 177.60 billion by 2019, growing considerably from its 2012 value of USD 78.54 billion. This market is expected to achieve a compounded annual growth rate of 12.3% between 2013 and 2019.

2017 Highlights:

Nanomed Meeting 2018conference will impact an attractive moment to meet people in the research field and therefore it takes a delight in opening a gate to meet the ability in the field, young researchers and potential speakers. World-renowned speakers, the most recent techniques, tactics, and the newest updates in fields Nanotechnology and engineering, Medical Nanotechnology, tissue engineering are hallmarks of this conference.

Meetings Internationalproudly announces the International Conference and Exhibition on Nanomedicine and Nanotechnology scheduled during Octobder 15-17, 2018 at Osaka, Japan . With a theme of “Challenges and Innovations in next generation medicine”.

Meetings Internationalprovides a Global Platform forNanotechnology, Biotech, Medical and Healthcare Professionals to Exchange Ideas, Knowledge and Networking at its 100+ International Conferences.

The popularity of Nanotechnology has increased significantly in recent years. TheNano marketis expected to reach USD 1,504.7 Billion by 2020 from USD 1,048.1 Billion in 2015, growing at a CAGR of 7.5% from 2015 to 2020. Nanotechnology market offers a promising approach for the delivery of various discoveries, trends,and many innovations. The technology is aimed at maximizing at the targeted site so as to increase the efficiency

Nanotechnology Meetingwill bring together key decision makers and innovators within this rapidly growing field. This intensive 3-Day program will examine various formulation and drug delivery strategies. The event will cover Pre-Formulation,Formulation Aspects, Pharmacokinetics and Pharmacodynamics, Drug Targeting, Drug Delivery Routes,Nano Drug Delivery Systems, Nanotechnology in Drug Delivery, Pharmaceutical Nanotechnology.

Join the industrys leading drug development executives from numerous leading organizations to discuss and hear unique take-home examples, case studies and multiple nano innovations and strategies to assist in reducing time-to-market on future Nano products.

Attend to gain an unmatched experience in theNanotechnologyfield.

Meetings InternationalNanomed Meeting 2018 will offer you an unmatched attendee experience. In addition to the many scientific sessions and take-home case study examples, you will leave this event with many other novel development strategies from some of our workshops and symposiums. Engage in dynamic conversation with your industry peers at our multiple networking sessions, and takeaway novel drug development and commercialization strategies, which could speed up time to market and save your organization millions. We hope you will join us in Dubai, UAE this november

Sincerely,

Operating Committee

CEO and Founder

Meetings International PTE LTD.

Meetings International Conferences invites all the participants across the globe to attend the Global Nanomedicine and Nanotechnology Conference scheduled during October 15-17, 2018 at Osaka, Japan. Nanomed Meeting 2018 provides a perfect symposium for scientists, engineers, directors of companies and students in the field of Nanotechnology to meet and share their knowledge. The scientific program paves a way to gather visionaries through the research talks and presentations and put forward many thought provoking strategies. It provides a premier technical forum for reporting and learning about the latest research and development, as well as for launching new applications and technology.

Track-1: Nanomedicine

Nanomedicineis simply the application of nanotechnologies in a healthcare setting and the majority of benefits that have already been seen involve the use ofnanoparticlesto improve the behaviour of drug substances. Today, nanomedicines are used globally to improve the treatments and lives of patients suffering from a range of disorders including ovarian and breast cancer, kidney disease, fungal infections, elevated cholesterol, menopausal symptoms, multiple sclerosis, chronic pain,asthmaand emphysema. Nanomedicine has the potential to develop radical new therapies based on an unprecedented control over both intracellular processes and the extracellular environment at the nanometer scale. To create precise solutions for intricate medical challenges in the area of wound healing, tissue regeneration and mitochondrial disease physical scientists, medical doctors, and industrial partners, work closely in the RadboudNanomedicine Alliance. The NationalNanotechnologyInitiative expects new commercial applications in the pharmaceutical industry that may include advanced drug delivery systems, new therapies, and in vivo imaging.

Related Associations & societies:

American society for Nanomedicine

British Society for Nanomedicine

European society for Nanomedicine

Track-2: Nanoscience and Technology

Nano Scienceis a technology conductedat theNano scale. It is the applications and study related to extremely small things that can be used around all the other fields of science, like chemistry, biology, physics, engineering and Materials sciences. These particles have the ability to control individual atoms and molecules .Nanotechnologyhas a huge potential to provide technological solutions to many problems in science, energy, physics, environment al and medical fields.

Related Associations & societies:

Indian society for Nanomedicine

European Foundation for Clinical Nanomedicine

French Society for Nanomedicine

Track-3: Molecular Nanotechnology

Molecular Nanotechnology a technological revolution which seeks nothing less than perfectibility. Molecular manufacturing technology can be clean and self-contained.Molecular Nanomanufacturing will slowly transform our connection towards matter and molecules as clear as the computer changed our relationship to information and bits. It will help accurate, inexpensive control of the structure of matter.

Related Associations & societies:

Iranian Society of Nanomedicine

NASA-JSC Area Nano Technology Study Group

Nano Meter-Scale Science and Technology Division of the American Vacuum Society

Track-4: Nano Particles

Nanoparticlesare particles between 1 and 100 nanometers in size. Innanotechnology, a particle is defined as a small object that behaves as a whole unit with respect to its transport and properties.Particlesare further classified according to diameter.Ultrafine particles are the same as nanoparticles and between 1 and 100 nanometers in size, fine particles are sized between 100 and 2,500 nanometers, and coarse particles cover a range between 2,500 and 10,000nanometers.

Related Associations & societies:

American Nano Society

Russian Nanotechnology Corporation

Sri Lanka Institute of Nanotechnology

Track-5: Advanced Nanomaterials

Nanomaterials are characterized as materials with no less than one outside measurement in the size extent from around 1-100 nanometers. Nanoparticles are items with each of the three outside measurements at the nanoscale1. Nanoparticles that are normally happening (e.g., volcanic powder, ash from woodland fires) or are the accidental side effects of ignition procedures (e.g., welding, diesel motors) are generally physically and synthetically heterogeneous and frequently termed ultrafine particles. Built nanoparticles are deliberately delivered and planned with particular properties identified with shape, size, surface properties and science. These properties are reflected in mist concentrates, colloids, or powders. Regularly, the conduct of nanomaterials might depend more on surface region than molecule arrangement itself. World interest for nanomaterials will rise more than more than two times to $5.5 billion in 2016. Nanotubes, nanoclays and quantum dabs will be the quickest developing sorts. The vitality stockpiling and era and development markets will offer the best development prospects. China, India and the US will lead picks up among countries.This study dissects the $2 billion world nanomaterial industry. It presents recorded interest information for the years 2001, 2006 and 2011, and gauges for 2016 and 2021 by material (e.g., metal oxides, chemicals and polymers, metals, nanotubes), market (e.g., social insurance, gadgets, vitality era and capacity, development), world area and for 15 nations.

Related Associations & societies:

Russian Nanotechnology Corporation

National Center for Nanoscience and Technology

International Association of Nanotechnology

Track-6: Nanotechnology in Tissue Engineering

Tissue engineering is one of the fast growing scientific area in this era which is used to create, repair, replace cells, tissues and organs by using cell or combinations of cells with biomaterials . biologically active molecules which helps to produce materials which very much resembles to body’s native tissue/tissues.

Related Associations & societies:

Center for Responsible Nanotechnology

Nanotechnology Industries

The Nanoethics Group

Track-7: Nanomedicine in Drug Delivery

Drug deliverydescribes the method and approach to delivering drugs or pharmaceuticals and other xenobiotic to their site of action within an organism, with the goal of achieving a therapeutic outcome. Issues of pharmacodynamics andpharmacokineticsare important considerations for drug delivery. Designing and developing novel drug delivery systems, with a focus on their application to disease conditions. Preclinical and clinical data related todrug delivery systems. Drug Delivery and Translational Research is a journal published by CRS, providing a unique forum for scientific publication of high-quality research that is exclusively focused onDrug Developmentand translational aspects of drug delivery. Drug distribution, pharmacokinetics, clearance, with drug delivery systems as compared to traditional dosing to demonstrate beneficial outcomes. Short-term and long-term biocompatibility of drug delivery systems, host response.Biomaterialswith growth factors for stem-cell differentiation in regenerative medicine and tissue engineering. Devices for drug delivery and drug/device combination products.

Related Associations & societies:

ASME Nanotechnology Institute

Institute of Occupational Medicine, Scotland, UK

Safe Nano, Europe’s Centre of Excellence on Nanotechnology Hazard and Risk

Track-8: Nano Pharmaceuticals

Nano pharmaceuticalsoffer the ability to detect diseases at much earlier stages and the diagnostic applications could build upon conventional procedures using nanoparticles. Nano pharmaceuticals represent an emerging field where the sizes of thedrug particleor a therapeutic delivery system work at the Nano scale. In the pharmaceutical industry, a long standing issue is the difficulty of delivering the appropriate dose of a particular active agent to specific disease site. Nano pharmaceuticals have enormous potential in addressing this failure oftraditional therapeuticswhich offers site-specific targeting of active agents. Such precision targeting via Nano pharmaceuticals reduces toxic systemic side effects, resulting in better patient compliance. In today world economy, a pharmaceutical industry faces enormous pressure to deliver high-quality products to patients while maintaining profitability. Therefore pharmaceutical companies are applyingnanotechnologyto enhance or supplement drug target discovery and drug delivery. Nano pharmaceutical reduces the cost ofdrug discovery, design & development and enhances the drug delivery process.

Related Associations & societies:

Nanometer-Scale Science and Technology Division of the American Vaccum Society

Scottish Center for NanoTechnology in Construction Materials

European NanoTechnology Gateway

Track-9: Nanotechnology in Healthcare

Nanomedicine affects almost all the aspects of healthcare. Nanomedicine helps to engineer novel and advanced tools for the treatment of various diseases and the improvement of human bio systems using molecular Nanotechnology. Cardiovascular diseases, Neurodegenerative disorders, Cancer, Diabetes, Infectious diseases, HIV/AIDS are the main diseases whose treatment can be benefitted by using Nanomedicine.

Related Associations & societies:

Erwin Schrdinger Society for Nanosciences (Austria)

American Academy of NanoMedicine

American Association for the Advancement of Science

Track-10: Biomaterials and Medical Devices

Biomaterials from healthcare viewpoint can be defined as materials those possess some novel properties that makes them appropriate to come in immediate association with the living tissue without eliciting any adverse immune rejection reactions. Biomaterials are in the service of mankind through ancient times but subsequent evolution has made them more versatile and has increased their usage.

Related Associations & societies:

Czech Nano Technology Industries Association

Royal Society-Nano Technology and Nano Science

Erwin Schrodinger Society for Nano Sciences

Track-11: Pharmaceutical Nanotechnology

Nanotechnology is the science which deals with the processes that occur at molecular level and of nanolength scale size. The major studies in the nanotechnology include nanosized particles, their function and behaviour with respect to other systems. The tremendous capabilities of nanoparticles have changed the perspective and scope of nanotechnology towards development into an adjuvant field for the remaining fields of life sciences. Nanotechnology is the ability to understand and control materials at the very smallest scales, from around 100 nm to the dimensions of single atoms; At this Nano scale the properties of these nanosized particles are vary from the conventional medicines.

Related Associations & societies:

Nano Technologies for Tomorrows Society

Nano Technology Research Association

Microscopy Society of America

Track-12: Recent Advances in Nanotechnology

Nano materials and devices play a major role in the field of pharmaceutical nanotechnology. Nanomaterials exhibit properties remarkably different from the properties of the bulk material due to the large surface area to volume ratio that increases the solubility and rate of absorption. Novel nanostructures will helpful for use as artificial tissue engineering and also help to integrate nanodevices with the nervous system that will restore vision and hearing, and build artificial limbs through the implant of new tissue. Nanotechnology is applied in the pharmaceutical industry in such areas as nanomedicine, tissue engineering, nanorobots, biosensors, biomarkers, image enhancement devices and implant technology. Investigations are currently being carried out on, among others, liposomes, dendrimers, metallic nanoparticles, polymeric nanoparticles, CNTs, quantum dots and nanofibres.

Related Associations & societies:

Nano Science and Technology Institute (NSTI)

Nanotechnology and Nanoscience Student Association (NANSA)

Schau-Platz NANO, Munich, Germany

Track-13: Major Challenges in Nanotechnology

At present, nanotechnology has been widely applied to the area of drug development. Nanoparticle-based therapeutics has the ability to overcome biological barriers and to deliver hydrophobic drugs and biologics effectively to the target sites of disease. The complexity of nanoparticles as multi-component 3D structures require careful design and engineering and reproducible scale-up and manufacturing process to achieve a consistent product. The safety and efficacy of nanoparticle-based medicines can be influenced by minor variations in multiple parameters and need to be carefully examined in preclinical and clinical examinations. Finally, nanoparticle-based medicines may have to represent additional development challenges and regulatory considerations compared with conventional medicines. Efforts are being made to produce unique category of therapeutic agents while there is generally a lack of regulatory standards in the examination of nanoparticle-based medicines.

International Conference And Exhibition OnNanotechnology and Nanomedicine

Osaka, Japan October 15-17, 2018

Theme:”Challenges and Innovations in next generation medicine”

STUDY BACKGROUND

While it appears inevitable that nanotechnology will have a broad and fundamental impact on many sectors of the U.S. economy, various technical, marketing and other hurdles need to be overcome before nanotechnology fulfills this promise. These challenges and differences of opinion regarding commercial applications are reflected in the widely diverging estimates of the U.S. and global nanotechnology markets.

Estimates of the global nanotechnology market in 2010 range from about $15.7 billion (the figure used in this report) to $1 trillion. By 2018, the market may be worth more than $2.4 trillion, according to different analysts. These differences reflect not only different analytical methods and assumptions, but also different definitions of the nanotechnology market (e.g., whether to include decades-old technologies such as carbon black rubber reinforcers and photographic silver, or whether to base the market value on nanotechnology inputs alone, as opposed to the total value of products that incorporate nanotechnology).

Perhaps as a reflection of the difficulty of quantifying the market for nanotechnologies, some analysts downplay the commercial dimensions of the nanotechnology market, and focus instead on the supply side, i.e., the development of new nanoscale technologies and applications. These analysts have made valuable contributions, raising investors awareness of and interest in nanotechnologies.

Read the original post:
Nanomed Meeting 2018 | Nanomedicine Conferences| Nanotechnology …

Read the Rest...

Nanobiotechnology Applications, Markets and Companies, 2017-2021 & 2026 – GlobeNewswire (press release)

§ September 7th, 2017 § Filed under Nano Medicine § Tagged Comments Off on Nanobiotechnology Applications, Markets and Companies, 2017-2021 & 2026 – GlobeNewswire (press release)

Dublin, Sept. 07, 2017 (GLOBE NEWSWIRE) — The “Nanobiotechnology Applications, Markets and Companies” report from Jain PharmaBiotech has been added to Research and Markets’ offering.

The report starts with an introduction to various techniques and materials that are relevant to nanobiotechnology. It includes some of the physical forms of energy such as nanolasers. Some of the technologies are scaling down such as microfluidics to nanofluidic biochips and others are constructions from bottom up. Application in life sciences research, particularly at the cell level sets the stage for role of nanobiotechnology in healthcare in subsequent chapters.

An increasing use of nanobiotechnology by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology will be applied at all stages of drug development – from formulations for optimal delivery to diagnostic applications in clinical trials. Many of the assays based on nanobiotechnology will enable high-throughput screening. Some of nanostructures such as fullerenes are themselves drug candidates as they allow precise grafting of active chemical groups in three-dimensional orientations. The most important pharmaceutical applications are in drug delivery. Apart from offering a solution to solubility problems, nanobiotechnology provides and intracellular delivery possibilities. Skin penetration is improved in transdermal drug delivery. A particularly effective application is as nonviral gene therapy vectors. Nanotechnology has the potential to provide controlled release devices with autonomous operation guided by the needs.

Nanomedicine is now within the realm of reality starting with nanodiagnostics and drug delivery facilitated by nanobiotechnology. Miniature devices such as nanorobots could carry out integrated diagnosis and therapy by refined and minimally invasive procedures, nanosurgery, as an alternative to crude surgery. Applications of nanobiotechnology are described according to various therapeutic systems. Nanotechnology will markedly improve the implants and tissue engineering approaches as well. Of the over 1,000 clinical trials of nanomedicines, approximately 100 are selected and tabulated in major therapeutic areas. Other applications such as for management of biological warfare injuries and poisoning are included. Contribution of nanobiotechnology to nutrition and public health such as supply of purified water are also included.

Future nanobiotechnology markets are calculated on the basis of the background markets in the areas of application and the share of this market by new technologies and state of development at any given year in the future. This is based on a comprehensive and thorough review of the current status of nanobiotechnology, research work in progress and anticipated progress. There is definite indication of large growth of the market but it will be uneven and cannot be plotted as a steady growth curve. Marketing estimates are given according to areas of application, technologies and geographical distribution starting with 2016. The largest expansion is expected between the years 2021 and 2026.

Profiles of 252 companies, out of over 500 involved in this area, are included in the last chapter along with their 183 collaborations.The report is supplemented with 51 Tables, 31 figures and 800 references to the literature.

Key Topics Covered:

Part I: Applications & Markets

1. Introduction

2. Nanotechnologies

3. Nanotechnologies for Basic Research Relevant to Medicine

4. Nanomolecular Diagnostics

5. Nanopharmaceuticals

6. Role of Nanotechnology in Biological Therapies

7. Nanodevices & Techniques for Clinical Applications

8. Nanooncology

9. Nanoneurology

10. Nanocardiology

11. Nanopulmonology

12. Nanoorthopedics

13. Nanoophthalmology

14. Nanomicrobiology

15. Miscellaneous Healthcare Applications of Nanobiotechnology

16. Nanobiotechnology and Personalized Medicine

17. Nanotoxicology

18. Ethical and Regulatory Aspects of Nanomedicine

19. Research and Future of Nanomedicine

20. Nanobiotechnology Markets

21. References

Part II: Companies

22. Nanobiotech Companies

For more information about this report visit https://www.researchandmarkets.com/research/xnnnck/nanobiotechnology

Read this article:
Nanobiotechnology Applications, Markets and Companies, 2017-2021 & 2026 – GlobeNewswire (press release)

Read the Rest...

Nanomedicine – Overview

§ September 6th, 2017 § Filed under Nano Medicine § Tagged Comments Off on Nanomedicine – Overview

Background

Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for curing disease or repairing damaged tissues, such as bone, muscle, or nerve. A nanometer is one-billionth of a meter, too small to be seen with a conventional lab microscope. It is at this size scale about 100 nanometers or less that biological molecules and structures operate in living cells.

The NIH vision for Nanomedicine is built upon the strengths of NIH funded researchers in probing and understanding the biological, biochemical and biophysical mechanisms of living tissues. Since the cellular machinery operates at the nanoscale, the primary goal of the program – characterizing the molecular components inside cells at a level of precision that leads to re-engineering intracellular complexes – is a monumental challenge.

The teams selected to carry out this initiative consist of researchers with deep knowledge of biology and physiology, physics, chemistry, math and computation, engineering, and clinical medicine. The choice and design of experimental approaches are directed by the need to solve clinical problems (e.g., treatment of sickle cell disease, blindness, cancer, and Huntingtons disease). These are very challenging problems, and great breakthroughs are needed to achieve the goals within the projected 10 year timeframe. The initiative was selected for the NIH Roadmap (now Common Fund) precisely because of the challenging, high risk goals, and the NIH team is working closely with the funded investigators to use the funds and the intellectual resources of the network of investigators to meet those challenges.

10 Year Program Design High Risk, High Reward

The Centers were funded with the expectation that the first half of the initiative would be more heavily focused on basic science with increased emphasis on application of this knowledge in the second five years. This was a novel, experimental approach to translational medicine that began by funding basic scientists interested in gaining a deep understanding of an intracellular nanoscale system and necessitated collaboration with clinicians from the outset in order to properly position work at the centers so that during the second half of the initiative, studies would be applied directly to medical applications. The program began with eight Nanomedicine Development Centers (NDCs), and four centers remain in the second half of the program.

Clinical Consulting Boards (CCBs)

The program has established Clinical Consulting Boards (CCBs) for each of the continuing centers. These boards consist of at least three disease-specific clinician-scientists who are experts in the target disease(s). The intent is for CCBs to provide advice and insight into the needs and barriers regarding resource and personnel allocations as well as scientific advice as needed to help the centers reach their translational goals. Each CCB reports directly to the NIH project team.

Translational Path

In 2011, the PIs of the NDCs worked with their CCBs to precisely define their translational goals and the translational research path needed to reach those goals by the end of the initiative in 2015. To facilitate this, the NIH project team asked them to develop critical decision points along their path. These critical decision points differ from distinct milestones because they may be adjusted based on successes, challenges, barriers, and progress. Similarly, the timing of these decision points may be revised as the centers progress. Research progress and critical decision points are revisited several times a year by the CCB and the NIH team, and when a decision point is reached, next steps are re-examined for relevance, feasibility and timing.

Transition plan

Throughout the program, various projects have been spun off of work at all the centers and most have received funding from other sources. This was by design as work at each center has been shifting from basic science to translational studies. Centers will not be supported by the common fund after 10 years. It is expected that work at the centers will be more appropriately funded by other sources. Pre-clinical targets will likely be developed, and the work at each center will be focused on a specific disease so the work will need to transition out of the experimental space of the common fund.

Support for the NIH Nanomedicine Initiative is provided by the NIH Common Fund, and a team of staff members from across the NIH oversees the program. You may direct questions or comments on the NIH Nanomedicine Initiative to Dr. Richard S. Fisher, Nanomedicine Project Team Leader (nano@nih.gov).

Originally posted here:
Nanomedicine – Overview

Read the Rest...

Global Nanomedicine Industry 2017 Market Growth, Trends and Demands Research Report – MENAFN.COM

§ September 6th, 2017 § Filed under Nano Medicine § Tagged Comments Off on Global Nanomedicine Industry 2017 Market Growth, Trends and Demands Research Report – MENAFN.COM

(MENAFN Editorial) iCrowdNewswire – Sep 4, 2017

The Global Nanomedicine Market 2017 Industry Research Report’ report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the Global major industry players in detail.

The Global Nanomedicine Market Research Report 2017 renders deep perception of the key regional market status of the Nanomedicine Industry on a global level that primarily aims the core regions which comprises of continents like Europe, North America, and Asia and the key countries such as United States, Germany, #China and Japan.

Complete report on Nanomedicine market report spread across 116 pages, profiling 12 companies and supported with tables and figuresavailable @

The report on ‘Global Nanomedicine Market is a professional report which provides thorough knowledge along with complete information pertaining to the Nanomedicine industry propos classifications, definitions, applications, industry chain summary, industry policies in addition to plans, product specifications, manufacturing processes, cost structures, etc.

The potential of this industry segment has been rigorously investigated in conjunction with primary market challenges. The present market condition and future prospects of the segment has also been examined. Moreover, key strategies in the market that includes product developments, partnerships, mergers and acquisitions, etc., are discussed. Besides, upstream raw materials and equipment and downstream demand analysis is also conducted.

Report Includes:-

The report cloaks the market analysis and projection of ‘Nanomedicine Market on a regional as well as global level. The report constitutes qualitative and quantitative valuation by industry analysts, first-hand data, assistance from industry experts along with their most recent verbatim and each industry manufacturers via the market value chain. The research experts have additionally assessed the in general sales and revenue generation of this particular market. In addition, this report also delivers widespread analysis of root market trends, several governing elements and macro-economic indicators, coupled with market improvements as per every segment.

For any Inquire before buying @

Global Nanomedicine market competition by top manufacturers/players, with Nanomedicine sales volume, Price (USD/MT), revenue (Million USD) and market share for each manufacturer/player; the top players including: GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc., SigmaTau Pharmaceuticals Inc., Smith & Nephew PLC, Stryker Corp, Teva Pharmaceutical Industries Ltd., UCB (Union chimique belge) S.A

The report is generically segmented into six parts and every part aims on the overview of the Nanomedicine industry, present condition of the market, feasibleness of the investment along with several strategies and policies. Apart from the definition and classification, the report also discusses the analysis of import and export and describes a comparison of the market that is focused on the trends and development. Along with entire framework in addition to in-depth details, one can prepare and stay ahead of the competitors across the targeted locations. The fact that this market report renders details about the major market players along with their product development and current trends proves to be very beneficial for fresh entrants to comprehend and recognize the industry in an improved manner. The report also enlightens the productions, sales, supply, market condition, demand, growth, and forecast of the Nanomedicine industry in the global markets.

Buy a copy of this report @

Every region’s market has been studied thoroughly in this report which deals with the precise information pertaining to the Marketing Channels and novel project investments so that the new entrants as well as the established market players conduct intricate research of trends and analysis in these regional markets. Acknowledging the status of the environment and products’ up gradation, the market report foretells each and every detail.So as to fabricate this report, complete key details, strategies and variables are examined so that entire useful information is amalgamated together for the understanding and studying the key facts pertaining the global Nanomedicine Industry. The production value and market share in conjunction with the SWOT analysis everything is integrated in this report.

Table of Contents

1 Nanomedicine Market Overview 2 Global Nanomedicine Market Competition by Manufacturers 3 Global Nanomedicine Capacity, Production, Revenue (Value) by Region (2011-2016) 4 Global Nanomedicine Supply (Production), Consumption, Export, Import by Regions (2011-2016) 5 Global Nanomedicine Production, Revenue (Value), Price Trend by Type 6 Global Nanomedicine Market Analysis by Application 7 Global Nanomedicine Manufacturers Profiles/Analysis

8 Nanomedicine Manufacturing Cost Analysis 9 Industrial Chain, Sourcing Strategy and Downstream Buyers 10 Marketing Strategy Analysis, Distributors/Traders 11 Market Effect Factors Analysis 12 Global Nanomedicine Market Forecast (2016-2021) 13 Research Findings and Conclusion

About Us

Deep Research Reportsis digital database of syndicated market reports for global and #China industries. These reports offer competitive intelligence data for companies in varied market segments and for decision makers at multiple levels in these organizations. We provide 24/7 online and offline support to our customers.

Connect us

Hrishikesh Patwardhan

Corporate Headquarters

2nd floor, metropole,

Next to inox theatre,

Bund garden road,Pune-411001.

1 888 391 5441

MENAFN0509201700703403ID1095819074

Read the original here:
Global Nanomedicine Industry 2017 Market Growth, Trends and Demands Research Report – MENAFN.COM

Read the Rest...

Nanomedicine Research Journal

§ September 2nd, 2017 § Filed under Nano Medicine § Tagged Comments Off on Nanomedicine Research Journal

Nanomedicine Research Journal (Abbreviation: Nanomed Res J)

is an international, open access, peer-reviewed, electronic and print quarterly publication released by the Iranian Society of Nanomedicine (ISNM). Nanomedicine Research Journal publishes original research articles, review papers, mini review papers, case reports and short communications covering a wide range of field-specific and interdisciplinary theoretical and experimental results related to applications of nanoscience and nanotechnology in medicine including, but not limited to, diagnosis, treatment, monitoring, prediction and prevention of diseases, tissue engineering, nano bio-sensors, functionalized carriers and targeted drug delivery systems.

* Publication process of manuscripts submitted to Nanomed Res J is free of charge.

To see Acceptance timeline Please follow the link below:

Acceptance Timeline Diagram

About the publisher

Founded in 2011 by the leading ofSchool of Advanced Technologies in medicine (SATiM),Tehran University of Medical Sciences (TUMS) and Iran Nanotechnology Initiative Council, the Iranian Society of Nanomedicine (ISNM) attempts to promote and develop medical nanotechnology in Iran. For more information about the publisher, please visit us at http://isnm.ir/en/.

Read this article:
Nanomedicine Research Journal

Read the Rest...

Eureka Prizes for outstanding science mentor and world-first trials – UNSW Newsroom

§ August 30th, 2017 § Filed under Nano Medicine § Tagged Comments Off on Eureka Prizes for outstanding science mentor and world-first trials – UNSW Newsroom

UNSW Scientia Professor Justin Gooding has won the Eureka Prize for Outstanding Mentor to Young Researchers, in a night where 12 UNSW and affiliated teams were recognised for excellence.

Also winning one of the prestigious prizes was Dr Lucia Romani, Associate Professor Handan Wand and Professor John Kaldor from the Kirby Institute, and Dr Margot Whitfield from St Vincents Hospital, part of the Scabies Research Team with collaborators from The Murdoch Childrens Research Institute, the Menzies School of Health Research and the Ministries of Health of Fiji and Solomon Islands.

Professor Goodings program of individualised mentorship is credited with creating a buzz in his lab and an environment that is supporting a new breed of research leaders in bionanotechnology and nanomedicine.

He has been a champion of multi-disciplinary research at UNSWas founding co-director of the Australian Centre for NanoMedicine, which draws on the universitys strengths in the Faculties of Science, Engineering and Medicine, as well as the Childrens Cancer Institute of Australia.

Dr Margot Whitfield, Associate Professor Handan Wand, Professor John Kaldor, Dr Lucia Romani, Professor Justin Gooding.

The Scabies Research Group won the Eureka Prize for Infectious Diseases Research for two world-first trials involving mass administration of the drug ivermectin, which reduced the prevalence of scabies from 33% of the population to less than 2%.

They were led by Associate Professor Andrew Steer from the Murdoch Childrens Research Institute in collaboration with The Kirby Institute UNSW, St Vincents Hospital Sydney and Menzies School of Health Research.

UNSW had a record 12 finalists in the running at this year’s Eureka Prizes, Australia’smost high-profile science awards.

The full list of 2017 winners is available here.

Follow this link:
Eureka Prizes for outstanding science mentor and world-first trials – UNSW Newsroom

Read the Rest...

Nanomedicine Market Growth Opportunities for Distributers 2017 – Equity Insider (press release)

§ August 30th, 2017 § Filed under Nano Medicine § Tagged Comments Off on Nanomedicine Market Growth Opportunities for Distributers 2017 – Equity Insider (press release)

Global Nanomedicine Market Research Report 2017 to 2022 provides a unique tool for evaluating the market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date marketing information is essential to monitor performance and make critical decisions for growth and profitability. It provides information on trends and developments, and focuses on markets and materials, capacities and technologies, and on the changing structure of the Nanomedicine Market.

Companies Mentioned are GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc., Sigma-Tau Pharmaceuticals Inc., Smith & Nephew PLC, Stryker Corp, Teva Pharmaceutical Industries Ltd., UCB (Union chimique belge) S.A.

Primary sources are mainly industry experts from core and related industries, and suppliers, manufacturers, distributors, service providers, and organizations related to all segments of the industrys supply chain. The bottom-up approach was used to estimate the global market size of Nanomedicine based on end-use industry and region, in terms of value. With the data triangulation procedure and validation of data through primary interviews, the exact values of the overall parent market, and individual market sizes were determined and confirmed in this study.

Sample/Inquire at: https://www.marketinsightsreports.com/reports/08308548/global-nanomedicine-market-research-report-2017/inquiry

This report segments the global Nanomedicine market on the basis of types Regenerative Medicine, In-vitro & In-vivo Diagnostics, Vaccines, Drug Delivery. On the basis of application Clinical Cardiology, Urology, Genetics, Orthopedics, Ophthalmology.

Essential points covered in Global Nanomedicine Market 2017 Research are:-

This independent 116 page report guarantees you will remain better informed than your competition. With over 170 tables and figures examining the Nanomedicine market, the report gives you a visual, one-stop breakdown of the leading products, submarkets and market leaders market revenue forecasts as well as analysis to 2022.

The global Nanomedicine market consists of different international, regional, and local vendors. The market competition is foreseen to grow higher with the rise in technological innovation and M&A activities in the future. Moreover, many local and regional vendors are offering specific application products for varied end-users. The new vendor entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology.

Browse Full Report at: https://www.marketinsightsreports.com/reports/08308548/global-nanomedicine-market-research-report-2017

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Storage Area Network Switch in these regions, from 2012 to 2022 (forecast), covering

by Regions

The report provides a basic overview of the Nanomedicine industry including definitions, classifications, applications and industry chain structure. And development policies and plans are discussed as well as manufacturing processes and cost structures.

Then, the report focuses on global major leading industry players with information such as company profiles, product picture and specifications, sales, market share and contact information. Whats more, the Nanomedicine industry development trends and marketing channels are analyzed.

The research includes historic data from 2012 to 2016 and forecasts until 2022 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs. The report will make detailed analysis mainly on above questions and in-depth research on the development environment, market size, development trend, operation situation and future development trend of Nanomedicine on the basis of stating current situation of the industry in 2017 so as to make comprehensive organization and judgment on the competition situation and development trend of Nanomedicine Market and assist manufacturers and investment organization to better grasp the development course of Nanomedicine Market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

There are 15 Chapters to deeply display the global Nanomedicine market.

Chapter 1, to describe Nanomedicine Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Nanomedicine, with sales, revenue, and price of Nanomedicine, in 2016and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Nanomedicine, for each region, from 2012to 2017;

Chapter 5, 6, 7,8and 9, to analyze the key regions, with sales, revenue and market share by key countries in these regions;

Chapter 10and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2012 to 2017;

Chapter 12, Nanomedicine market forecast, by regions, type and application, with sales and revenue, from 2017to 2022;

Chapter 13, 14 and 15, to describe Nanomedicine sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Continued here:
Nanomedicine Market Growth Opportunities for Distributers 2017 – Equity Insider (press release)

Read the Rest...

Impact of Existing and Emerging Europe Nanomedicine Market … – MilTech

§ August 29th, 2017 § Filed under Nano Medicine § Tagged Comments Off on Impact of Existing and Emerging Europe Nanomedicine Market … – MilTech

The global Nanomedicine Market size was estimated at USD XX billion in 2017. Technological advancements coupled with relevant applications in early disease diagnosis, preventive intervention, and prophylaxis of chronic as well as acute disorders is expected to bolster growth in this market.

Download Sample Pages @http://www.kminsights.com/request-sample-33081

Nanotechnology involves the miniaturization of larger structures and chemicals at nanometric scale which has significantly revolutionized drug administration, thus influencing adoption of the technology through to 2022.

Expected developments in nanorobotics owing to the rise in funding from the government organizations is expected to induce potential to the market. Nanorobotics engineering projects that are attempting to target the cancer cells without affecting the surrounding tissues is anticipated to drive progress through to 2022.

Ability of the nanotechnology to serve in diagnostics as well as the therapeutic sector at the same time as a consequence of its characteristic principle to is anticipated to augment research in this sector. Furthermore, utilization of DNA origami for healthcare applications is attributive for the projected growth.

The global nanomedicine market is segmented based on modality, application, indication, and region. Based on application, it is classified into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others.

On the basis of indication, it is categorized into oncological diseases, neurological diseases, urological diseases, infectious diseases, ophthalmological diseases, orthopedic disorders, immunological diseases, cardiovascular diseases, and others. Based on modality, it is bifurcated into treatments and diagnostics.

The global market is driven by emerging technologies for drug delivery, increase in adoption of nanomedicine across varied applications, rise in government support & funding, growth in need for therapies with fewer side effects, and cost-effectiveness of therapies. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth.

Download Sample Pages @http://www.kminsights.com/request-sample-33081

Contact:

Mr.Mannansales@kminsights.com+1 (888) 278-7681

About Us:Key Market Insights is a stand-alone organization with a solid history of advancing and exchanging market research reports and logical surveys delivered by our numerous transnational accomplices, which incorporate both huge multinationals and littler, more expert concerns.

Read the original post:
Impact of Existing and Emerging Europe Nanomedicine Market … – MilTech

Read the Rest...

Expert Radiologist and Clinician Scientist, Michelle S. Bradbury, MD, PhD, is to be Recognized as a 2017 Top Doctor … – PR NewsChannel (press…

§ August 29th, 2017 § Filed under Nano Medicine § Tagged Comments Off on Expert Radiologist and Clinician Scientist, Michelle S. Bradbury, MD, PhD, is to be Recognized as a 2017 Top Doctor … – PR NewsChannel (press…

Michelle Bradbury MD, PhD, who is a Professor of Radiology, Director of Intraoperative Imaging, and Co-Director of an National Cancer Institute awarded Nanomedicine Center (MSK-Cornell Center for Translation of Cancer Nanomedicines), has been named a 2017 Top Doctor in New York City, New York. Top Doctor Awards is dedicated to selecting and honoring those healthcare practitioners who have demonstrated clinical excellence while delivering the highest standards of patient care.

Dr. Michelle S. Bradbury is a highly experienced physician who has been in practice for over two decades. Her career in medicine started in 1997, when she graduated from the George Washington University School of Medicine and Health Sciences in Washington, D.C. An internship, residency and then fellowship followed, all completed at Wake Forest University in Winston-Salem, North Carolina. Dr. Bradbury also holds a Doctor of Philosophy Degree from the Massachusetts Institute of Technology.

Dr. Bradbury is certified by the American Board of Radiology in both Diagnostic Radiology and Neuroradiology. She is particularly renowned, however, as a leading expert in nanomedicine and in neuroradiology, using CT and MRI imaging of the brain, neck and spine to diagnose conditions of the nervous system. Alongside her work in this field she has been at the forefront of nanomedicine research and clinical trials.

Dr. Bradbury keeps up to date with the latest advances in her field through her active membership of professional organizations including the American College of Radiology, the World Molecular Imaging Congress, and the American Society of Nanomedicine. Her expertise and dedication makes Dr. Michelle S. Bradbury a very deserving winner of a 2017 Top Doctor Award.

About Top Doctor Awards

Top Doctor Awards specializes in recognizing and commemorating the achievements of todays most influential and respected doctors in medicine. Our selection process considers education, research contributions, patient reviews, and other quality measures to identify top doctors

Read the rest here:
Expert Radiologist and Clinician Scientist, Michelle S. Bradbury, MD, PhD, is to be Recognized as a 2017 Top Doctor … – PR NewsChannel (press…

Read the Rest...

New report shares details about Europe’s nanomedicine market – WhaTech

§ August 24th, 2017 § Filed under Nano Medicine § Tagged Comments Off on New report shares details about Europe’s nanomedicine market – WhaTech

The global nanomedicine market size was estimated at USD XX billion in 2017. Technological advancements coupled with relevant applications in early disease diagnosis, preventive intervention, and prophylaxis of chronic as well as acute disorders is expected to bolster growth in this market.

Nanotechnology involves the miniaturization of larger structures and chemicals at nanometric scale which has significantly revolutionized drug administration, thus influencing adoption of the technology through to 2022.

Download Sample Pages @www.kminsights.com/request-sample-33081

Expected developments in nanorobotics owing to the rise in funding from the government organizations is expected to induce potential to the market. Nanorobotics engineering projects that are attempting to target the cancer cells without affecting the surrounding tissues is anticipated to drive progress through to 2022.

Ability of the nanotechnology to serve in diagnostics as well as the therapeutic sector at the same time as a consequence of its characteristic principle to is anticipated to augment research in this sector. Furthermore, utilization of DNA origami for healthcare applications is attributive for the projected growth.

The global nanomedicine market is segmented based on modality, application, indication, and region. Based on application, it is classified into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others.

On the basis of indication, it is categorized into oncological diseases, neurological diseases, urological diseases, infectious diseases, ophthalmological diseases, orthopedic disorders, immunological diseases, cardiovascular diseases, and others. Based on modality, it is bifurcated into treatments and diagnostics.

This report studies sales (consumption) of Nanomedicine in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, the top player coveringAffilogicLTFNBergmannstrostGrupo PraxisBiotechrabbitBraccoMaterials Research?CentreCarlina technologiesChemConnectionCIC biomaGUNECIBER-BBNContiproCristal TherapeuticsDTIEndomagneticsFraunhofer ICT-IMMTecnaliaTeknikerGIMACIMDEAIstec CNRSwedNanoTechVicomtechVITO NV

The global market is driven by emerging technologies for drug delivery, increase in adoption of nanomedicine across varied applications, rise in government support & funding, growth in need for therapies with fewer side effects, and cost-effectiveness of therapies. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth.

In addition, increase in out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are anticipated to provide numerous opportunities for the market growth.

Download Sample Pages @www.kminsights.com/request-sample-33081

More:
New report shares details about Europe’s nanomedicine market – WhaTech

Read the Rest...

Growth in the Global Nanomedicine Market 2017-2021 trends … – satPRnews (press release)

§ August 24th, 2017 § Filed under Nano Medicine § Tagged Comments Off on Growth in the Global Nanomedicine Market 2017-2021 trends … – satPRnews (press release)

Global Nanomedicine Market 2017-2021

This Nanomedicine market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Download sample pages of this report:http://tinyurl.com/y7bs9wea

Data integration and capabilities are analyzed to support the findings and study the predicted geographical segmentations. Various key variables and regression models were considered to calculate the trajectory of Nanomedicine market. Detailed analysis is explained and given importance to with best working models.

Geographically, the segmentation is done into several key regions like North America, Middle East & Africa, Asia Pacific, Europe and Latin America. The production, consumption, revenue, shares in mill UDS, growth rate of Nanomedicine market during the forecast period of 2017 to 2021 is well explained.

The ongoing market trends of Nanomedicine market and the key factors impacting the growth prospects are elucidated. With increase in the trend, the factors affecting the trend are mentioned with perfect reasons. Top manufactures, price, revenue, market share are explained to give a depth of idea on the competitive side.

Each and every segment type and their sub types are well elaborated to give a better idea about this market during the forecast period of 2017 to 2021 respectively.

Download sample pages of this report:http://tinyurl.com/y7bs9wea

About Us:Key Market Insights is a stand-alone organization with a solid history of advancing and exchanging market research reports and logical surveys delivered by our numerous transnational accomplices, which incorporate both huge multinationals and littler, more expert concerns.

Contact:

Mr. Mannansales@kminsights.com+1 (888) 278-7681

Read more:
Growth in the Global Nanomedicine Market 2017-2021 trends … – satPRnews (press release)

Read the Rest...

Are nano drug delivery and telehealth solutions a deadly combo for disease? – EPM Magazine

§ August 24th, 2017 § Filed under Nano Medicine § Tagged Comments Off on Are nano drug delivery and telehealth solutions a deadly combo for disease? – EPM Magazine

Incorporating telehealth solutions into new drug delivery technologies like nanomedicines can potentially give pharmaceuticals the edge they need to win the fight against disease.

Creating drug delivery systems that utilise telehealth solutions like smartphone technologies, Bluetooth, IoT, wearable technologies, and AI would help pharmaceutical companies save money in clinical trials by reducing the financial burden caused by poor medical adherence and provide better patient outcomes through real-time data analysis. Telehealth solutions provide physicians and clinical trial scientists direct access to their patient, and can provide them with valuable data that will improve their performance and the patients health. Access to real-time patient health data is an opportunity for pharmaceutical companies to develop a range of smart drug delivery systems that could potentially change the way an estimated 50% of the population deal with their chronic diseases.

With large numbers living with some form of chronic disease, pharmaceutical companies must incorporate telehealth tech into their drug delivery systems to collect real-time data and use the data to improve patient treatment, clinical trial outcomes and apply the data for further research.

The drug delivery systems available in todays market are honestly not that impressive. A Bluetooth-enabled inhaler, smart automatic injectors, and smart pills are definitely technologies that benefit patient care but lack innovative pizzazz. Bluetooth technology was first introduced in mobile phones in 2000. It has taken 17 years to implement the data-gathering technology into an inhaler/auto injector, often at times requiring user actions like downloading from an SD card. I am surprised it has taken this long for pharma to get where it is today, but there is truly hope on the horizon, with recent advancements in nanotechnology.

The future of pharmaceuticals and population health lies in the utilisation of telehealth solutions like the Internet of Nano Things (IoNT), wearables, smartphones and the latest drug delivery tech likesmart nanoplatforms, nanoparticles/nanomedicines, and nanosensors. These recent technological advancements in drug delivery should change the way we understand and cure diseases.

Northwestern University has developed a nanoplatform that can assess the effectiveness of nanomaterials in regulating gene expression. The nanoplatform allows scientists to observe nanomedicines and particle behaviour in an in vivo setting. Theres no doubt that the relationship between nanomedicines and IoNT is inevitable however there are issues like patient health risks and security that must be taken into account.

Whenever the internet is involved, the issue of security should be raised. Are nanomedicines saving patients lives, while also putting them at risk of body hacking? Although programmable particles are sending signals from within the patients body and providing beneficial information for the doctor/scientist, the idea that a signal can be hacked is a horrific reality. Nanoparticle manipulation is possible by gaining access to the particles using ultrasound and electromagnetic field waves making hacking feasible but extremely difficult and complex. The next question is what happens to the nanoparticles after treatment? Will they pose a later threat and become an access point for hackers?

Nanomedicines, after entering the human body, travel throughout reaching the organs, the bloodstream, the lungs and even crossing the semi-permeable membranes into cells delivering the drugs to exactly the right place at the right time. Their disbursement depends on size and programming. Nanoparticles are metal-based, carbon-based, composites, and dendrimers, and are excreted from the body via faeces and urine. The liver and spleen can also decompose them, however up to 30% can remain in the body for an extended period of time and potentially become an access point for hacking.

Combining telehealth solutions and nanomedicines will benefit the populations health by presenting effective treatments for chronic and deadly pathologies and provide scientists and doctors previously unattainable data for analysis. This previously elusive data has become available thanks to Northwestern Universitys Nanoplatform, which successfully provides imaging of the nanomedicines effectiveness on the MGMT gene, a chemo-resistant cancer gene. This data has already provided a better understanding of the nanomedicines mechanics and provided researchers with the best time, after treatment with nanomedicines, to administer chemotherapy.

Nanoparticles appear to be a solution that can improve the health of the population, however there are still potential risks for patients. Although most nanoparticles are tested in labs and in vitro, a few potential health risks have been observed. Risks like the creation of a protein corona (a shifting population of different molecules) can influence the immune defence system and mistakenly allow the corona to penetrate good non-targeted tissues. The clumping of protein molecules can also be linked to multiple pathologies, including amyloidosis. Some nanoparticles have also been linked to genetic mutations, DNA damage, and chromosomal alterations, however they are rarely attributed to all three at once. It is quite clear that more research and testing is required to truly understand the future of nanomedicine and its effects on the human body.

Nanomedicines target a specific area within the body, can delay activation and have the potential to relay real-time data for analysis. Scientists and doctors can finally have a real-time view of their treatments and understand the pathology and its interaction with the medicines, leading to data that will help the healthcare industry save lives, defeat disease, and save money. The benefits in combining telehealth solutions with nano drug delivery systems is evident and it is the colossal leap forward that the industry has been looking for in the never-ending fight with diseases like cancer.

Read more from the original source:
Are nano drug delivery and telehealth solutions a deadly combo for disease? – EPM Magazine

Read the Rest...

Director of The Baby Place at Park Ridge Health earns doctorate in nursing practice – Mountain Xpress (blog)

§ August 24th, 2017 § Filed under Nano Medicine § Tagged Comments Off on Director of The Baby Place at Park Ridge Health earns doctorate in nursing practice – Mountain Xpress (blog)

Press release:

Park Ridge Health is celebrating the success of Beth Cassidy, DNP, MSN, RNC-OB, NE-BC, Director of The Baby Place at Park Ridge Health who recently earned her Doctorate of Nursing Practice degree.Cassidy has been the director of The Baby Place at Park Ridge Health since 2011. In her time as director, The Baby Place has earned national recognition for its exemplary care for mothers and babies across Western North Carolina, including the Womens Choice Award as one of Americas Best Hospitals for Obstetrics.Cassidy says she embarked on the journey to earn her doctorate because of her love of learning and her love for empowering her team. As a unit director in a small facility, which I prefer, you have to be an educator, said Cassidy. My team supported me through the two full years of doctorate work in anticipation of how we would turn it around to be directly applicable to each of them and their goals of expanding their skills.Park Ridge Health makes it a priority to discover the goals each of our employees may have for their lives and then encourages and empowers them to achieve those goals, said Jimm Bunch, Park Ridge Health President and CEO. Beths determination and drive to expand her skills as a caregiver and as a nursing leader are an inspiration, not only to her team, but to the entire Park Ridge Health family.The Baby Place at Park Ridge Health has become the labor and delivery center of choice for hundreds of families across Western North Carolina. Cassidy works as part of a caring team of Physicians, Nurses, Midwives, Lactation Consultants, Childbirth Educators and other support personnel to bring families the best possible care, so they can focus on one of the most important experiences of their lives. The Baby Place at Park Ridge Health cares for women through their choices which range from traditional delivery, to natural labor, to midwifery. In 2016, Cassidy and her team helped welcome nearly 650 babies into the world. To learn more about The Baby Place at Park Ridge Health, call 855.PRH.LIFE (855.774.5433) or visit myPRH.com.About Park Ridge Health: Founded in 1910, Park Ridge Health is dedicated to meeting the health care needs of our growing communities, providing high-quality, compassionate care in a Christian environment. In 1984, Park Ridge Health became a member of Adventist Health System, a family of 45 exceptional, faith-based hospitals across the country that operate independently to deliver care and services that best meet the needs of their communities. Leading the way in many medical firsts for the region, Park Ridge Health is the first hospital in Western North Carolina to offer nanomedicine in the operating room with the Nanolock Spinal technology and the only hospital in the region with the Pro-Axis Spine Surgery table. Park Ridge Health provides personalized care at more than 30 locations, offering a dedicated network of more than 250 physicians and providers, cardiac care & rehabilitation, emergency services, nationally awarded cancer care, state-of-the-art surgical care, full-service orthopedic care, an award-winning labor & delivery experience, and a full range of imaging services. For more information about Park Ridge Health or to find a physician, please visit parkridgehealthor call 855.PRH.LIFE (855.774.5433).

View original post here:
Director of The Baby Place at Park Ridge Health earns doctorate in nursing practice – Mountain Xpress (blog)

Read the Rest...

Lungs in Space – Texas Medical Center (press release)

§ August 22nd, 2017 § Filed under Nano Medicine § Tagged Comments Off on Lungs in Space – Texas Medical Center (press release)

Space travel can cause a lot of stress on the human body as the change in gravity, radiation and other factors creates a hostile environment. While much is known about how different parts of the body react in space, how lungs are affected by spaceflight has received little attention until now, say researchers at The University of Texas Medical Branch at Galveston and Houston Methodist Research Institute.

That will change, though, once their research project, which aims to grow lungs in space, reaches the International Space Station. UTMB and HMRI researchers say what they learn from the study could have real implications for astronauts, as well as those still on Earth, and could lead to future therapeutics.

We know a lot about what happens in space to bones, muscle, the heart and the immune system, but nobody knows much about what happens to the lungs, said Joan Nichols, a professor of Internal Medicine and Microbiology and Immunology, and associate director for research and operations for the Galveston National Laboratory at UTMB. We know that there are some problems with lungs in space flight, but that hasnt been closely looked into. We hope to find out how lung cells react to the change in gravity and the extreme space environment, and then that can help us protect astronauts in space, as well as the lungs of regular people here on Earth.

This investigation represents the third of four collaborative projects currently active at the HMRIs Center for Space Nanomedicine. The center, directed by Alessandro Grattoni, chairman and associate professor of the Department of Nanomedicine at HMRI, focuses on the investigation of nanotechnology-based strategies for medicine on Earth and in space. The research is supported by the Center for the Advancement of Science in Space, NASA and HMRI.

Scientists from UTMB and HMRI prepared bioreactor pouches that include lung progenitor and stem cells and pieces of lung scaffolding. The scaffolding is the collagen and elastin frame on which lung cells grow. Space X successfully launched the payload containing these pouches Aug. 14 on its 12th Commercial Resupply Services mission (CRS-12) from NASAs Kennedy Space Center in Florida and arrived at the International Space Station Aug. 16. On the ISS, the cells are expected to grow on the scaffold in a retrofitted bioreactor.

Once the lung cells have returned to Earth, researchers will look for the development of fibrosis, the structure of the tissues and the response of immune cells, among other changes and damage that could occur to the lung cells. Lung injuries have been found to accelerate in space, and it is through close study of those cells that therapeutics hopefully could be developed.

Nichols and Dr. Joaquin Cortiella, a professor and director of the Lab of Tissue Engineering and Organ Regeneration at UTMB, have successfully grown lungs in their lab in Galveston, but now they will see if astronauts can do the same in zero gravity. Jason Sakamoto, affiliate professor and former co-chair of the Department of Nanomedicine at HMRI, has applied his novel organ decellularization process and nanotechnology-based delivery systems to support this overall lung regeneration effort.

We have experience working with the Center for the Advancement of Science in Space to study our nanotechnologies in action on the International Space Station, Grattoni said. However, we are extremely excited to be a part of this clinical study, since it may play a pivotal role in how we approach future space travel in terms of preserving astronaut health. What we learn during this fundamental experiment could lead to science-fiction-like medical advancements, where organ regeneration becomes a reality in both deep space and here on Earth.

Researchers at HMRI will take the results from UTMB and work on developing therapeutics that could help astronauts, as well as people on Earth.

This exploration will provide fundamental insight for the collaborative development of cell-based therapies for autoimmune diseases, hormone deficiencies and other issues, Grattoni said.

Continued here:
Lungs in Space – Texas Medical Center (press release)

Read the Rest...

Global Nanomedicine Market Research Report 2016 satPRnews – satPRnews (press release)

§ August 20th, 2017 § Filed under Nano Medicine § Tagged Comments Off on Global Nanomedicine Market Research Report 2016 satPRnews – satPRnews (press release)

Global Nanomedicine Market Research Report 2016

2016 Global Nanomedicine Market Report is a professional and in-depth research report on the worlds major regional market conditions of the Nanomedicine industry, focusing on the main regions (North America, Europe and Asia) and the main countries (United States, Germany, Japan and China).

Download sample pages of this report: https://goo.gl/cBLFx6

The report firstly introduced the Nanomedicine basics: definitions, classifications, applications and industry chain overview; industry policies and plans; product specifications; manufacturing processes; cost structures and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, capacity utilization, supply, demand and industry growth rate etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The report includes six parts, dealing with: 1.) basic information; 2.) the Asia Nanomedicine industry; 3.) the North American Nanomedicine industry; 4.) the European Nanomedicine industry; 5.) market entry and investment feasibility; and 6.) the report conclusion.

Download sample pages of this report: https://goo.gl/cBLFx6

About Us:

Key Market Insights is a stand-alone organization with a solid history of advancing and exchanging market research reports and logical surveys delivered by our numerous transnational accomplices, which incorporate both huge multinationals and littler, more expert concerns.

Contact:

sales@kminsights.com

+1 (888) 278-7681

Continued here:
Global Nanomedicine Market Research Report 2016 satPRnews – satPRnews (press release)

Read the Rest...

Growth in Nanomedicine market-2017 trends, forecasts, analysis … – satPRnews (press release)

§ August 18th, 2017 § Filed under Nano Medicine § Tagged Comments Off on Growth in Nanomedicine market-2017 trends, forecasts, analysis … – satPRnews (press release)

The report firstly introduced the Nanomedicine basics: definitions, classifications, applications and industry chain overview; industry policies and plans; product specifications; manufacturing processes; cost structures and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, capacity utilization, supply, demand and industry growth rate etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Download sample pages of this report: http://www.kminsights.com/request-sample-1892

Nanomedicine is a branch of medicine that applies the knowledge and tools of nanotechnology to the prevention and treatment of disease. Nanomedicine involves the use of nanoscale materials, such as biocompatible nanoparticles and nanorobots, for diagnosis, delivery, sensing or actuation purposes in a living organism.

The ongoing market trends of Nanomedicine market and the key factors impacting the growth prospects are elucidated. With increase in the trend, the factors affecting the trend are mentioned with perfect reasons. Top manufactures, price, revenue, market share are explained to give a depth of idea on the competitive side.

Each and every segment type and their sub types are well elaborated to give a better idea about this market during the forecast period of 2017respectively.

Download sample pages of this report: http://www.kminsights.com/request-sample-1892

About Us:Key Market Insights is a stand-alone organization with a solid history of advancing and exchanging market research reports and logical surveys delivered by our numerous transnational accomplices, which incorporate both huge multinationals and littler, more expert concerns.

Contact:sales@kminsights.com+1 (888) 278-7681

Read more from the original source:
Growth in Nanomedicine market-2017 trends, forecasts, analysis … – satPRnews (press release)

Read the Rest...

Lungs in space: research project could lead to new lung therapeutics – Phys.Org

§ August 16th, 2017 § Filed under Nano Medicine § Tagged Comments Off on Lungs in space: research project could lead to new lung therapeutics – Phys.Org

Space travel can cause a lot of stress on the human body as the change in gravity, radiation and other factors creates a hostile environment. While much is known about how different parts of the body react in space, how lungs are affected by spaceflight has received little attention until now, say researchers at The University of Texas Medical Branch at Galveston and Houston Methodist Research Institute.

That will change, though, once their research project, which aims to grow lungs in space, reaches the International Space Station. UTMB and HMRI researchers say what they learn from the study could have real implications for astronauts, as well as those still on Earth, and could lead to future therapeutics.

“We know a lot about what happens in space to bones, muscle, the heart and the immune system, but nobody knows much about what happens to the lungs,” said Joan Nichols, a professor of Internal Medicine and Microbiology and Immunology, and associate director for research and operations for the Galveston National Laboratory at UTMB. “We know that there are some problems with lungs in space flight, but that hasn’t been closely looked into. We hope to find out how lung cells react to the change in gravity and the extreme space environment, and then that can help us protect astronauts in space, as well as the lungs of regular people here on Earth.”

This investigation represents the third of four collaborative projects currently active at the HMRI’s Center for Space Nanomedicine. The center, directed by Alessandro Grattoni, chairman and associate professor of the Department of Nanomedicine at HMRI, focuses on the investigation of nanotechnology-based strategies for medicine on Earth and in space. The research is supported by the Center for the Advancement of Science in Space, NASA and HMRI.

Scientists from UTMB and HMRI prepared bioreactor pouches that include lung progenitor and stem cells and pieces of lung scaffolding. The scaffolding is the collagen and elastin frame on which lung cells grow. Space X successfully launched the payload containing these pouches Aug. 14 on its 12th Commercial Resupply Services mission (CRS-12) from NASA’s Kennedy Space Center in Florida and is expected to arrive at the International Space Station Aug. 16. Once on the ISS, the cells are expected to grow on the scaffold in a retrofitted bioreactor.

Once the lung cells have returned to Earth, researchers will look for the development of fibrosis, the structure of the tissues and the response of immune cells, among other changes and damage that could occur to the lung cells. Lung injuries have been found to accelerate in space, and it is through close study of those cells that therapeutics hopefully could be developed.

Nichols and Dr. Joaquin Cortiella, a professor and director of the Lab of Tissue Engineering and Organ Regeneration at UTMB, have successfully grown lungs in their lab in Galveston, but now they will see if astronauts can do the same in zero gravity. Jason Sakamoto, affiliate professor and former co-chair of the Department of Nanomedicine at HMRI, has applied his novel organ decellularization process and nanotechnology-based delivery systems to support this overall lung regeneration effort.

“We have experience working with the Center for the Advancement of Science in Space to study our nanotechnologies in action on the International Space Station,” Grattoni said. “However, we are extremely excited to be a part of this clinical study, since it may play a pivotal role in how we approach future space travel in terms of preserving astronaut health. What we learn during this fundamental experiment could lead to science-fiction-like medical advancements, where organ regeneration becomes a reality in both deep space and here on Earth.”

Researchers at HMRI will take the results from UTMB and work on developing therapeutics that could help astronauts, as well as people on Earth.

“This exploration will provide fundamental insight for the collaborative development of cell-based therapies for autoimmune diseases, hormone deficiencies and other issues,” Grattoni said.

Explore further: Image: Testing astronauts’ lung health

View post:
Lungs in space: research project could lead to new lung therapeutics – Phys.Org

Read the Rest...

siRNA Treatment for Brain Cancer Stops Tumor Growth in Mouse Model – Technology Networks

§ August 10th, 2017 § Filed under Nano Medicine § Tagged Comments Off on siRNA Treatment for Brain Cancer Stops Tumor Growth in Mouse Model – Technology Networks

Early phase Northwestern Medicine research published in the journal Proceedings of the National Academy of Sciences has demonstrated a potential new therapeutic strategy for treating deadly glioblastoma brain tumors.

The strategy involves using lipid polymer-based nanoparticles to deliver molecules to the tumors, where the molecules shut down key cancer drivers called brain tumor-initiating cells (BTICs).

BTICs are malignant brain tumor populations that underlie the therapy resistance, recurrence and unstoppable invasion commonly encountered by glioblastoma patients after the standard treatment regimen of surgical resection, radiation and chemotherapy, explained the studys first author, Dou Yu, MD, PhD, research assistant professor of Neurological Surgery.

Using mouse models of brain tumors implanted with BTICs derived from human patients, the scientists injected nanoparticles containing small interfering RNA (siRNA) short sequences of RNA molecules that reduce the expression of specific cancer-promoting proteins directly into the tumor. In the new study, the strategy stopped tumor growth and extended survival when the therapy was administered continuously through an implanted drug infusion pump.

This major progress, although still at a conceptual stage, underscores a new direction in the pursuit of a cure for one of the most devastating medical conditions known to mankind, said Yu, who collaborated on the research with principal investigator Maciej Lesniak, MD, Michael J. Marchese Professor of Neurosurgery and chair of the Department of Neurological Surgery.

Glioblastoma is particularly difficult to treat because its genetic makeup varies from patient to patient. This new therapeutic approach would make it possible to deliver siRNAs to target multiple cancer-causing gene products simultaneously in a particular patients tumor.

In this study, the scientists tested siRNAs that target four transcription factors highly expressed in many glioblastoma tissues but not all. The therapy worked against classes of glioblastoma BTICs with high levels of those transcription factors, while other classes of the cancer did not respond.

This paints a picture for personalized glioblastoma therapy regimens based on tumor profiling, Yu said. Customized nanomedicine could target the unique genetic signatures in any specific patient and potentially lead to greater therapeutic benefits.

The strategy could also apply to other medical conditions related to the central nervous system not just brain tumors.

Degenerative neurological diseases or even psychiatric conditions could potentially be the therapeutic candidates for this multiplexed delivery platform, Yu said.

Before scientists can translate this proof-of-concept research to humans, they will need to continue refining the nanomedicine platform and evaluating its long-term safety. Still, the findings from this new research provide insight for further investigation.

Nanomedicine provides a unique opportunity to advance a therapeutic strategy for a disease without a cure. By effectively targeting brain tumor-initiating stem cells responsible for cancer recurrence, this approach opens up novel translational approaches to malignant brain cancer, Lesniak summed up.

This article has been republished frommaterialsprovided by Northwestern University. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference

Dou Yu, Omar F. Khan, Mario L. Suv, Biqin Dong, Wojciech K. Panek, Ting Xiao, Meijing Wu, Yu Han, Atique U. Ahmed, Irina V. Balyasnikova, Hao F. Zhang, Cheng Sun, Robert Langer, Daniel G. Anderson, Maciej S. Lesniak. Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proceedings of the National Academy of Sciences, 2017; 201701911 DOI: 10.1073/pnas.1701911114

Read more:
siRNA Treatment for Brain Cancer Stops Tumor Growth in Mouse Model – Technology Networks

Read the Rest...

Targeting tumours: IBBME researchers investigate biological barriers to nanomedicine delivery – U of T Engineering News

§ August 9th, 2017 § Filed under Nano Medicine § Tagged Comments Off on Targeting tumours: IBBME researchers investigate biological barriers to nanomedicine delivery – U of T Engineering News

For cancer patients, understanding the odds of a treatments success can be bewildering. The same drug, applied to the same type of cancer, might be fully successful on one persons tumour and do nothing for another one. Physicians are often unable to explain why.

Now, U of T Engineering researchers are beginning to understand one of the reasons.Abdullah Syed and Shrey Sindhwani, both PhD candidates,and their colleagues at the Institute of Biomaterials & Biomedical Engineering (IBBME) have created a technology to watch nanoparticles traveling into tumours revealing barriers that prevent their delivery to targets and the variability between cancers.

The biggest thing weve noticed is that nanoparticles face multiple challenges posed by the tumour itself on their way to cancer cells, says Sindhwani, an MD-PhD student in the Integrated Nanotechnology & Biomedical Sciences Laboratory of Professor Warren Chan (IBBME). Syed and Sindhwani co-published their findings online June 22, and on the cover of the Journal of the American Chemical Society. So the treatment might work for a while or worse, theres just enough of the drug for the cancer to develop resistance. This could be prevented if we can figure out the ways in which these barriers stop delivery and distribution of the drug throughout the cancer.

Tiny nanoparticles offer great hope for the treatment of cancer and other disease because of their potential to deliver drugs to targeted areas in the body, allowing more precise treatments with fewer side effects. But so far the technology hasnt lived up to its promise, due to delivery and penetration problems.

To dismantle this roadblock, the two graduate students searched for a way to better view the particles journey inside tumours. They discovered that the tough-to-see particles could be illuminated by scattering light off their surfaces.

The sensitivity of our imaging is about 1.4 millionfold higher, says Syed. First, we make the tissue transparent, then we use the signal coming from the particles to locate them. We shine a light on the particles and it scatters the light. We capture this scattering light to learn the precise location of the nanoparticles.

It was already understood that nanoparticles were failing to accumulate in tumours, thanks to a meta-analysis of the field done by Chans group. But the researchers have developed technologies to look at nanoparticle distribution in 3D, which provides a much fuller picture of how the particles are interacting with the rest of the tumour biology. The goal is to use this technology to gather knowledge for developing mathematical principles of nanoparticle distribution in cancer, similar to the way principles exist for understanding the function of the heart, says Syed.

And because each tumour is unique, this technology and knowledge base should help future scientists to understand the barriers to drug delivery on a personalized basis, and to develop custom treatments.

The next step is to understand what in cancers biology stops particles from fully penetrating tumours and then to develop ways to bypass cancers defences.

But the technology is also useful for diseases other than cancer. With the help of Professor Jennifer Gommerman, an researcher in the Department of Immunology who studies multiple sclerosis (MS), Syed and Sindhwani captured 3D images of lesions in a mouse model mimicking MS using nanoparticles.

This is going to be very valuable to anyone trying to understand disease or the organ system more deeply, says Sindhwani. And once we understand barriers that dont allow drugs to reach their disease site, we can start knocking them down and improving patient health adds Syed.

Read the original post:
Targeting tumours: IBBME researchers investigate biological barriers to nanomedicine delivery – U of T Engineering News

Read the Rest...

« Older Entries





Page 11234..1020..»